---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-046852"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:50:59.873377+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Avalo receives $69.4M from full warrant exercise; cash runway into at least 2027

## Summary
- Gross proceeds of $69.4M from exercise of 11,967,526 warrants at $5.796933/share; total private placement proceeds now $185M.
- Cash runway expected into at least 2027, funding Phase 2 LOTUS trial and expansion of AVTX-009 program.
- As of Nov 8, 2024: 10,463,633 common shares outstanding; 24,895.92 Series C Preferred shares convertible into 24.9M common shares subject to ownership limits.
- CEO states focus on hidradenitis suppurativa trial and identifying next inflammatory indication for AVTX-009.

## SEC filing metadata
- accession: 0001628280-24-046852
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828024046852/0001628280-24-046852-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828024046852/avtx-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-046852
- JSON: https://secwatch.observer/filing/0001628280-24-046852.json
- Plain text: https://secwatch.observer/filing/0001628280-24-046852.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.